Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.39 |
| ▸ | CHRNG | P07510 | 4/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.39 |
| ▸ | CHRND | Q07001 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13646104 | 1.00 | CA14 (0.50) | CA14CA12SLC6A3SMN1; SMN2SLC6A2 | |
| SCHEMBL13166671 | 1.00 | CA14 (0.50) | CA14CA12SLC6A3SMN1; SMN2SLC6A2 | |
| SCHEMBL15837231 | 0.83 | SLC6A3 (0.39) | CA14CA12SLC6A3SMN1; SMN2SLC6A2 | |
| SCHEMBL15497667 | 0.83 | SLC6A3 (0.39) | CA14CA12SLC6A3SMN1; SMN2SLC6A2 | |
| SCHEMBL11186119 | 0.81 | METAP2 (0.43) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL7857076 | 0.81 | METAP2 (0.43) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL18430098 | 0.81 | CA14 (0.35) | CA14CA12SLC6A3SMN1; SMN2SLC6A2 | |
| SCHEMBL15497665 | 0.80 | SLC6A3 (0.37) | CA14CA12SLC6A3SMN1; SMN2SLC6A2 | |
| SCHEMBL20329438 | 0.80 | CA14 (0.42) | CA14CA12SMN1; SMN2ALDH1A1CA1 | |
| SCHEMBL17403508 | 0.79 | SLC6A3 (0.42) | CA14CA12SLC6A3SMN1; SMN2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021250531-A1 | 4-(4,5-DIHYDRO-1H-PYRAZOL-1-YL)PYRIMIDINE COMPOUND AS CANNABINOID RECEPTOR (CB1 RECEPTOR) ANTAGONISTS AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 주식회사 종근당 | 2021-12-16 | — | — | WO | disclosed |
| US-10208035-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-10-26 | — | — | US | disclosed |
| US-9676771-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-06-13 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7507820-B2 | Diazaphosphacycles | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1255542-A4 | SUBSTITUTED AMINO ACIDS AS NEUTRAL SPHINGOMYELINASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1255542-A1 | SUBSTITUTED AMINO ACIDS AS NEUTRAL SPHINGOMYELINASE INHIBITORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6306911-B1 | ENZYME INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2001056560-A1 | SUBSTITUTED AMINO ACIDS AS NEUTRAL SPHINGOMYELINASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| US-6114310-A | THERAPY FOR MICROBIAL INFECTIONS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208035-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | CCR8, CDK8, CHD8 | CA14 3863/4885CA12 4127/4885SLC6A3 2108/4885 |
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | CCR8, CDK8, CHD8 | CA14 3863/4885CA12 4127/4885SLC6A3 2108/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | CA14 3387/4885CA12 4301/4885SLC6A3 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.